Home › Burkitt Lymphoma › Nevada
Burkitt Lymphoma clinical trials in Nevada
6 studies for Burkitt Lymphoma are looking for participants at sites in Nevada.
Cities in Nevada
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Sep 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Sep 2, 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
- Summerlin Hospital Medical Center, Las Vegas
- Renown Regional Medical Center, Reno
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
- Summerlin Hospital Medical Center, Las Vegas
- Renown Regional Medical Center, Reno
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.